MiRNAs Delivery for Cancer-associated Fibroblasts' Activation and Drug Resistance in Cancer Microenvironment

Overview

Journal Endocr Metab Immune Disord Drug Targets

Publisher Bentham Science Publishers

Specialties Allergy & Immunology
Endocrinology
Infectious Diseases
Pharmacology

Date 2023 Aug 24

PMID 37612874

Authors

Sara Anajafi

Mahdi Paryan

Amineh Khoshnazar

Masoud Soleimani

Samira Mohammadi-Yeganeh

Affiliations

Soon will be listed here.

Abstract

Cancer-associated fibroblasts (CAFs) as a major component of cancer stroma contribute to diverse procedures of most solid tumors and might be a targeted cancer therapy approach. Their specified features, related signaling pathways, distinct biomarkers, and sub-populations need to be deciphered. There is a need for CAF extraction or induction for in vitro investigations. Some miRNAs could activate CAF-like phenotype and they also interfere in CAF-mediated drug resistance, aggressiveness, and metastatic behaviors of several cancer cell types. Due to the complex relevance of miRNA and CAFs, these non-coding oligonucleotides may serve as attractive scope for anti-cancer targeted therapies, but the lack of an efficient delivery system is still a major hurdle. Here, we have summarized the investigated information on CAF features, isolation, and induction procedures, and highlighted the miRNA-CAF communications, providing special insight into nano-delivery systems.

References

Kalluri R . The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016; 16(9):582-98. DOI: 10.1038/nrc.2016.73. View

Mohla S . Tumor microenvironment. J Cell Biochem. 2007; 101(4):801-4. DOI: 10.1002/jcb.21320. View

Whiteside T . The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008; 27(45):5904-12. PMC: 3689267. DOI: 10.1038/onc.2008.271. View

Galbo Jr P, Zang X, Zheng D . Molecular Features of Cancer-associated Fibroblast Subtypes and their Implication on Cancer Pathogenesis, Prognosis, and Immunotherapy Resistance. Clin Cancer Res. 2021; 27(9):2636-2647. PMC: 8102353. DOI: 10.1158/1078-0432.CCR-20-4226. View

Anari F, Ramamurthy C, Zibelman M . Impact of tumor microenvironment composition on therapeutic responses and clinical outcomes in cancer. Future Oncol. 2018; 14(14):1409-1421. DOI: 10.2217/fon-2017-0585. View

Chen X, Song E . Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2018; 18(2):99-115. DOI: 10.1038/s41573-018-0004-1. View

Barker H, Cox T, Erler J . The rationale for targeting the LOX family in cancer. Nat Rev Cancer. 2012; 12(8):540-52. DOI: 10.1038/nrc3319. View

Liu T, Zhou L, Li D, Andl T, Zhang Y . Cancer-Associated Fibroblasts Build and Secure the Tumor Microenvironment. Front Cell Dev Biol. 2019; 7:60. PMC: 6492564. DOI: 10.3389/fcell.2019.00060. View

Paterlini-Brechot P . About seed and soil. Cancer Microenviron. 2014; 7(3):91-3. PMC: 4275543. DOI: 10.1007/s12307-014-0163-5. View

10.

Dvorak H . Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986; 315(26):1650-9. DOI: 10.1056/NEJM198612253152606. View

11.

Liu T, Han C, Wang S, Fang P, Ma Z, Xu L . Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. J Hematol Oncol. 2019; 12(1):86. PMC: 6714445. DOI: 10.1186/s13045-019-0770-1. View

12.

Rieske P, Krynska B, Azizi S . Human fibroblast-derived cell lines have characteristics of embryonic stem cells and cells of neuro-ectodermal origin. Differentiation. 2005; 73(9-10):474-83. DOI: 10.1111/j.1432-0436.2005.00050.x. View

13.

Polanska U, Acar A, Orimo A . Experimental generation of carcinoma-associated fibroblasts (CAFs) from human mammary fibroblasts. J Vis Exp. 2011; (56):e3201. PMC: 3227206. DOI: 10.3791/3201. View

14.

Dourado R, Porto L, Leitao A, Cerqueira P, Dos Santos J, Ramalho L . Immunohistochemical Characterization of Cancer-associated Fibroblasts in Oral Squamous Cell Carcinoma. Appl Immunohistochem Mol Morphol. 2017; 26(9):640-647. DOI: 10.1097/PAI.0000000000000486. View

15.

Katoh M . Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers. Clin Sci (Lond). 2019; 133(8):953-970. DOI: 10.1042/CS20180845. View

16.

Cazet A, Hui M, Elsworth B, Wu S, Roden D, Chan C . Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. Nat Commun. 2018; 9(1):2897. PMC: 6057940. DOI: 10.1038/s41467-018-05220-6. View

17.

Doldi V, Callari M, Giannoni E, DAiuto F, Maffezzini M, Valdagni R . Integrated gene and miRNA expression analysis of prostate cancer associated fibroblasts supports a prominent role for interleukin-6 in fibroblast activation. Oncotarget. 2015; 6(31):31441-60. PMC: 4741617. DOI: 10.18632/oncotarget.5056. View

18.

Yoshida G . Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways. J Exp Clin Cancer Res. 2020; 39(1):112. PMC: 7296768. DOI: 10.1186/s13046-020-01611-0. View

19.

Sahai E, Astsaturov I, Cukierman E, DeNardo D, Egeblad M, Evans R . A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020; 20(3):174-186. PMC: 7046529. DOI: 10.1038/s41568-019-0238-1. View

20.

Duluc C, Moatassim-Billah S, Chalabi-Dchar M, Perraud A, Samain R, Breibach F . Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance. EMBO Mol Med. 2015; 7(6):735-53. PMC: 4459815. DOI: 10.15252/emmm.201404346. View